drugset / Trial / NCT00250874
Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To study the pharmacokinetic profile of the therapeutic schedule in order to demonstrate absence of negative interactions among the 3 drugs administered
Timeline
- Start
- 2003-12
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 35 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |